The United States Patent and Trademark Office (USPTO) has issued patent US12583920B2 to the University of Maryland, Baltimore. This patent covers novel compositions and methods for treating or preventing Alzheimer's disease by utilizing antagonists for LRP1 and/or SorLA. The core of the invention lies in reducing the internalization and trafficking of tau proteins within neuronal cells, a key pathological hallmark of Alzheimer's disease.

This patent grant is primarily relevant for pharmaceutical and biotechnology companies involved in Alzheimer's research and development. While it does not impose direct compliance obligations on regulated entities, it signifies intellectual property protection for a specific therapeutic approach. Companies operating in this space should be aware of this patent to ensure their own research and development activities do not infringe upon the granted claims, particularly concerning the use of LRP1/SorLA antagonists in Alzheimer's treatments.